Antineutrophil cytoplasmic antibodies‐associated glomerulonephritis: From bench to bedside

Chronic Diseases and Translational Medicine - Tập 4 - Trang 187-191 - 2018
Yong-Xi Chen1, Xiao-Nong Chen1
1Department of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Tóm tắt

Abstract

Antineutrophil cytoplasmic antibodies (ANCA)‐associated vasculitis (AAV) is a group of autoimmune disorders that predominantly affects small vessels. The onset of the disease is closely associated with ANCA. Renal involvement, also known as ANCA‐associated glomerulonephritis (AGN), is one of the most common manifestations of AAV. In this mini‐review, we described the clinical and pathological features of AGN. We then focused on recent studies on the mechanism of acute kidney lesions, including fibrinoid necrosis and crescent formation. Following the basic aspects of kidney injury in AGN, we demonstrated the clinical importance of kidney injury in determining the outcome of patients with AGN. The prognostic value of the 2010 Histopathological Classification of AGN and validating studies were summarized. Finally, treatment and novel therapeutic strategies were introduced addressing the importance of optimizing management of this patient population.


Tài liệu tham khảo

10.1002/art.37715 10.3899/jrheum.110931 Chen Y.X., 2007, Propylthiouracil‐associated antineutrophil cytoplasmic autoantibody‐positive vasculitis: retrospective study of 19 cases, J Rheumatol, 34, 2451 10.1016/S0140-6736(06)69114-9 10.1159/000348633 10.1159/000165117 10.1136/annrheumdis-2016-210942 10.1038/nrneph.2012.107 10.1016/S0272-6386(03)00025-8 Chen Y.X., 2014, Clinical analysis of ANCA‐associated renal vasculitis patients with chronic dialysis, Clin Exp Rheumatol, 32, S5 Chen Y.X., 2011, Application of RIFLE criteria in Chinese patients with ANCA‐associated renal vasculitis, Clin Exp Rheumatol, 29, 951 10.1038/nrrheum.2016.123 10.3899/jrheum.160866 10.1046/j.1523-1755.2000.00080.x 10.1111/j.1523-1755.2004.00632.x 10.5414/CN107254 10.1046/j.1523-1755.2003.00843.x 10.1146/annurev-immunol-032414-112220 10.1159/000364945 10.2215/CJN.03230314 10.1681/ASN.2015050511 10.1016/j.ajpath.2017.05.003 10.1093/ndt/gfv288 10.1093/ndt/gfn586 10.1681/ASN.2005091013 10.1681/ASN.2010050477 10.1681/ASN.2005080870 10.1046/j.1523-1755.2002.00605.x 10.3899/jrheum.170006 10.2215/CJN.04800516 10.2215/CJN.01210214 10.1681/ASN.2007010090 10.2215/CJN.02500317 10.1136/annrheumdis-2017-211123 Guillevin L., 2017, Maintenance treatment of ANCA‐associated vasculitides, Clin Exp Rheumatol, 35, 199 10.1056/NEJMoa1213277 10.1136/annrheumdis-2014-206095 10.1164/rccm.200507-1144OC 10.1056/NEJMoa1404231 10.1056/NEJMoa0909905 10.1016/j.autrev.2017.04.007 10.1681/ASN.2016111179